OVERVIEW

CME: Fabry disease: Updates from the 15th Annual worldsymposium is organized by ScientiaCME.

Release Date: Jul 25, 2019
Expiration Date: Jul 25, 2021

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 hours (0.125 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-19-013-H01-P. CPE credit effective 4/28/19 and expires 4/28/21.

Description:
Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels. A defect in the enzyme alpha galactosidase A results in glycosphingolipid accumulation, ultimately leading to multi-organ dysfunction and the patient’s premature death. Early symptoms, which occur during childhood, involve pain and may include Raynaud phenomenon, paresthesias, and arthralgia in the extremities and proximal limbs, as well as impaired gastrointestinal emptying, resulting in abdominal pain, diarrhea, early satiety, postprandial bloating, nausea, and vomiting. In adulthood, the disease’s impact spreads beyond and begins to affect the cardiac and renal systems.

Program Objectives:
By the end of the session the participant will be able to:
• Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material recently presented
• Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
• Describe emerging therapies for Fabry disease based on research recently presented
• Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research recently presented